UPCC 17822:A Phase 1, Multi-center, Open-label, Dose finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC 94676 in Subjects with Metastatic Castration-resistant Prostate Cancer
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The primary purpose of this clinical research study is to test, for the first time in people, the safety (any good or bad effects) of the new experimental drug, CC-94676.
We would like to rely on WCG IRB as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 851627
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
